In contrast to IL-17A, IL-22 may exert additional pathogenic effects apart from those mediated by IL-4/IL-13 because the anti-IL-22 antibody fezakinumab shows weak therapeutic potential for treating patients with severe AD [46]. This evidence concerns the gene IL4 and Alzheimer disease.